The Evaluation of the Effectiveness of the Application of Sulodexide for the Combined Treatment of the Patients Presenting with Trophic Ulcers on the Lower Extremities of Venous Etiology

Katorkin, S. E.

doi:10.17116/flebo20159435-41

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We excluded 41 studies that were originally considered as potentially eligible. The reasons for exclusion were: no clinical data reported (n = 13) [12,13,29,[39][40][41][73][74][75][76][77][78][79], indication other than CVD with data on CVD symptoms not available/not extractable (n = 13) [80][81][82][83][84][85][86][87][88][89][90][91][92], no extractable data on symptoms (n = 9) [36,[93][94][95][96][97][98][99][100][101], preliminary partial publication (n = 3) [102][103][104], data reported but not stratified by treatment (n = 1) [105], review (n = 1) [47] or duplicate (n = 1) [98].…”

Section: Excluded Studiesmentioning

confidence: 99%

Sulodexide for the Symptoms and Signs of Chronic Venous Disease: A Systematic Review and Meta-analysis

Bignamini

Matuška²

2020

Adv Ther

View full text Add to dashboard Cite

Introduction: Chronic venous disease (CVD) is a common condition associated with valvular dysfunction, venous hypertension and endothelial inflammation. Sulodexide facilitates the healing of venous ulcers and is frequently used in patients with CVD without ulcer. This review assessed the efficacy and safety of sulodexide for treatment of signs and symptoms of lower extremity CVD. Methods: We searched MEDLINE, EMBASE, CINAHL and AMED as well as the Cochrane Central Register of Controlled Trials and the World Health Organisation (WHO) International Clinical Trials Registry Platform Search Portal. We also manually searched potentially relevant journals, conference proceedings and journal supplements. Any study monitoring any effect of sulodexide in patients with CVD at any stage of the disease, classified or non-classified, was considered. Treatment effects were estimated using standardised mean differences (SMDs), mean differences (MDs) and risk ratios (RRs), as appropriate. We calculated 95% confidence intervals (CIs) and heterogeneity (Q, tau and I 2 ). Results: The search found 64 studies, but only 23 provided data on 7153 participants (mean age 55 years; 68% female). The 13 studies providing extractable quantitative information included 1901 participants (mean age 55.2 years; 65% female). Sulodexide decreased the intensity of pain, cramps, heaviness, oedema and total symptom score and reduced inflammatory mediators in patients with CVD. The risk of adverse events (AEs) was not different between sulodexide and placebo or heparan sulphate (RR 1.31, 95% CI 0.74-2.32; I 2 = 0%; 270 participants). The overall risk of AEs with sulodexide was low: 3% (95% CI 1-4%) estimated from 3656 participants. Conclusion: Sulodexide was found to have a beneficial venoactive effect on the major signs and symptoms of CVD such as pain, cramps, heaviness and oedema without increasing the risk of AEs. It is also likely to exert a systemic effect on the course of CVD by interfering with inflammatory chemokines. Key Summary PointsThe majority of validated approaches for the management of chronic venous disease (CVD) are relatively invasive and may be limited by patient acceptance; compression is instead usually associated with poor compliance.This systematic review assessed the efficacy and safety of sulodexide for treatment of signs and symptoms of lower extremity CVD by reviewing the literature and conducting a meta-analysis.Sulodexide had a beneficial venoactive effect on the major signs and symptoms of CVD, such as pain, cramps, heaviness and oedema, without increasing the risk of adverse events. It is also likely to exert a systemic effect on the course of CVD by interfering with inflammatory chemokines.

show abstract

Section: Excluded Studiesmentioning

confidence: 99%

Sulodexide for the Symptoms and Signs of Chronic Venous Disease: A Systematic Review and Meta-analysis

Bignamini

Matuška²

2020

Adv Ther

View full text Add to dashboard Cite

show abstract

Sulodexide in the Treatment of Chronic Venous Insufficiency: Results of the All-Russian Multicenter ACVEDUCT Program

et al. 2020

View full text Add to dashboard Cite

Sulodexide in the treatment of post-thrombotic disease complicated by the development of trophic defects of the lower extremities in patients with COVID-19 pneumonia

Zudin

Shapoval

2021

Aterotromboz

View full text Add to dashboard Cite

Introduction. The problem of care for patients with trophic venous ulcers remains an urgent medical and social problem, which has been aggravated again against the background of the COVID-19 pandemic in 2020-2021. As is now known, after a COVID-19 viral infection, most patients with cardiovascular diseases experience a significant exacerbation of these ailments. This is also true for postthrombotic lower extremity disease (PTD). Many patients with edematous or edematous-painful forms of PTB after COVID-19-associated pneumonia experience formation of trophic ulcers of the distal parts of the lower extremities.Aim. To study characteristic features of the course of ulcerative process in PTB in patients after COVID-19-associated pneumonia and to search safe and effective means, accelerating wound epithelialization in such patients.Material and methods. Efficiency of sulodexide use in conservative therapy of 16 patients with PTB, in whom trophic defects (venous ulcers) of the lower third of the shin and foot first appeared after pneumonia due to SARS-CoV-2 infection, was evaluated. At the same time, trophic ulcers were highly resistant to conventional therapy aimed at their healing. All 16 patients were unable to achieve epithelialization more than one month after the occurrence of trophic ulcers. Results. According to the results of this study it was found that the use of sulodexide as an angiotropic agent having, among other things, anti-inflammatory effect on the vessel wall in patients with trophic ulcers formed after COVID-19-associated pneumonia is justified.Conclusions. The treatment of trophic defects of the lower limbs in patients with PTB after COVID-19-associated pneumonia has a number of regular features. Sulodexide showed high efficacy as an angiotropic agent, whose pharmacological properties are adequate to the pathogenesis of trophic ulcers taking into account the course of infection caused by SARS-CoV-2.

show abstract

The Evaluation of the Effectiveness of the Application of Sulodexide for the Combined Treatment of the Patients Presenting with Trophic Ulcers on the Lower Extremities of Venous Etiology

Cited by 3 publications

References 9 publications

Sulodexide for the Symptoms and Signs of Chronic Venous Disease: A Systematic Review and Meta-analysis

Sulodexide for the Symptoms and Signs of Chronic Venous Disease: A Systematic Review and Meta-analysis

Sulodexide in the Treatment of Chronic Venous Insufficiency: Results of the All-Russian Multicenter ACVEDUCT Program

Sulodexide in the treatment of post-thrombotic disease complicated by the development of trophic defects of the lower extremities in patients with COVID-19 pneumonia

Contact Info

Product

Resources

About